RxDoctor Payments Data

Judith Veis, MD

Nephrology · Washington, DCNPI 1336113950

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $386 of the $435 with a category attached, or 88.7%. 7 manufacturers reported payments, led by Travere Therapeutics, Inc. at 33.8% of the total. That places this record below the midpoint for nephrology clinicians in DC, where the typical reported total is $513.

$435in general payments, 2019–2025

Across 8 payments — averaging $54.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$147
  • Calliditas Therapeutics US Inc.$98
  • Cormedix Inc.$52
  • Akebia Therapeutics Inc$49
  • Caris MPI, Inc.$35
  • Nuwellis, Inc.$31
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$38689%
  • Education$4911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$435 in reported general payments places this provider in the 45th percentile of 62 nephrology providers in District of Columbia.

See all nephrology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$273,070
Medicare patients
522
Services billed
1,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl15$78,805
JardianceEmpagliflozin44$72,201
VelphoroSucroferric Oxyhydroxide29$53,097
LokelmaSodium Zirconium Cyclosilicate36$35,551
FarxigaDapagliflozin Propanediol42$31,150
RenvelaSevelamer Carbonate14$29,853
KerendiaFinerenone20$21,361
EliquisApixaban24$15,846
Sevelamer Carbonate43$10,647
Clonidine24$2,283
Calcium Acetate25$2,151
Eplerenone15$1,914
Nifedipine ErNifedipine47$1,282
Losartan Potassium141$1,147
Tacrolimus11$1,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$22$53,09729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 62 nephrology providers in District of Columbia.

Other nephrology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →